CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?
- PMID: 34895488
- DOI: 10.1016/S1470-2045(21)00648-3
CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?
Conflict of interest statement
NNS has participated in an advisory board meeting for Vor Biopharma and has held leadership or committee positions with the American Society of Hematology, American Society for Transplantation and Cellular Therapy, and Center for International Blood and Marrow Transplant Research. NGH declares no competing interests. The content of this publication does not necessarily reflect the views of policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government.
Comment on
-
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources